A description is given of the use of polyanionic and polyanionically-derivatised natural polysaccharides or non-derivatised natural polysaccharides for inhibiting alkaline phosphatase and of oral compositions for preventing bacterial plaque, which comprises (a) 0 to 10% by weight of at least one linear molecularly dehydrated polyphosphate salt, and (b) 0.0001 to 5% by weight of a polyanionic or polyanionically-derivatised natural polysaccharide.

Una descripción se da del uso de polisacáridos naturales polyanionic y polyanionically-derivatizados o de polisacáridos naturales no-derivatizados para inhibir el phosphatase alcalino y de las composiciones orales para prevenir la placa bacteriana, que abarca (a) 0 a el 10% en peso de por lo menos una sal molecular deshidratada linear del polyphosphate, y (b) 0.0001 a el 5% en peso de un polisacárido natural polyanionic o polyanionically-derivatizado.